Category Archives: Patently BIOtech

Supreme Court Decision on Web Content Delivery to Impact Biotech Patents

Zuhn

Earlier this month, in Limelight Networks, Inc. v. Akamai Technologies, Inc., the Supreme Court issued a decision that will likely impact patents directed to methods for treating or diagnosing diseases.  In Limelight Networks, the Court reversed the appellate court’s finding that Limelight had infringed U.S. Patent No. 6,108,703, which is assigned to the Massachusetts Institute of Technology and is exclusively licensed to Akamai Technologies.  In particular, the Court determined that a defendant is not liable Read More >

Patently BIOtech  |  Leave a comment  |  Email This Post
Tags: , , , , , ,

IP at the 2014 BIO International Convention

San Diego

Securing and maintaining intellectual property protection for the next generation of biotech innovation faces new challenges and opportunities.  Come learn about current issues and those just on the horizon before they affect your practice and your company. Keynote Speakers in the IP Track: Director General Francis Gurry, World Intellectual Property Organization Judge Randall R. Rader, United States Court of Appeals for the Federal Circuit Acting Director Michelle Lee, United States Patent and Trademark Office IP Read More >

Patently BIOtech  |  Leave a comment  |  Email This Post
Tags: , , , , , ,

Nautilus v. Biosig, Baxter v. Fresenius and Limelight v. Akamai

Supreme Court

BIO weighed in on three Supreme Court cases in the last few months whose outcome could change the IP landscape for biotechnology companies. BIO’s amicus brief in Nautilus v. Biosig Instruments argues that the petitioner misrepresents the Federal Circuit’s definiteness test and seeks to litigate an issue not properly before this court.  Petitioner’s approach radically departs from established law and practice.  Finally the petitioner’s approach would destabilize the patent system as it would inject substantial Read More >

Patently BIOtech  |  Leave a comment  |  Email This Post
Tags: , , , , , , ,

Corporate-Sponsored University Research Valuable for Further Innovation

SBIR Reauthorization Moves Forward

New research published in Nature, Technology Transfer: Industry-funded academic inventions boost innovation, provides data undermining “assumptions that corporate-funded academic research is less accessible and useful to others.” After reviewing empirical evidence covering 20 years of inventions in the University of California system the authors find that: “Corporate-sponsored research is surprisingly valuable for further innovation. Data collected over 20 years at nine campuses and three national laboratories administered by the University of California show that corporate-sponsored Read More >

Patently BIOtech  |  Leave a comment  |  Email This Post
Tags: , , , , , ,

Gene Patent Questions Remain: USPTO Issues Examiner Guidelines

Supreme Court

The new Patent Office guidance, issued March 4, extends the Supreme Court’s legal logic into areas that were neither mentioned nor decided in the Myriad case itself. Myriad went to the Supreme Court exclusively on the question whether human genes are patentable. And human genetic diagnostic testing was the only context in which the Supreme Court thought about this question. The Supreme Court also acknowledged that it is not a scientific expert, and perhaps recognized Read More >

Patently BIOtech  |  Leave a comment  |  Email This Post
Tags: , ,